Monogram Orthopaedics, Inc. (MGRM)
Automate Your Wheel Strategy on MGRM
With Tiblio's Option Bot, you can configure your own wheel strategy including MGRM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MGRM
- Rev/Share 0.0
- Book/Share 0.332
- PB 17.4412
- Debt/Equity 0.0283
- CurrentRatio 7.004
- ROIC -1.112
- MktCap 206633115.0
- FreeCF/Share -0.3652
- PFCF -16.0681
- PE -12.7345
- Debt/Assets 0.0216
- DivYield 0
- ROE -1.2644
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MGRM | ROTH MKM | -- | Buy | -- | $4 | Dec. 9, 2024 |
News
MGRM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Monogram Technologies to Zimmer Biomet
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030.
Read More
Shareholder Alert: The Ademi Firm Investigates Whether Monogram Technologies Inc. is Obtaining a Fair Price for its Public Shareholders
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Monogram (NASDAQ: MGRM) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Monogram will receive $4.04 per share in cash, representing an equity value of appro.
Read More
MGRM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Monogram Technologies Inc. Is Fair to Shareholders
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Monogram Technologies Inc. (NASDAQ: MGRM) to Zimmer Biomet Holdings, Inc. is fair to Monogram shareholders. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development.
Read More
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Indiana and AUSTIN, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for …
Read More
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas , July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for …
Read More
Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones.
Read More
Monogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in India
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral
Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TEXAS / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will …
Read More
Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce its partnership with Urvin, a private, verified message board exclusively for active Monogram shareholders. This platform offers a way for shareholders to communicate directly with each other while providing Monogram with an additional tool to provide important company updates and reach the broadest possible shareholder audience.
Read More
Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India AUSTIN, TX / ACCESS Newswire / February 26, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its 510(k) premarket filing submission to the U.S. Food and Drug Administration ("FDA") for the Company's mBôs TKA System. The Company has completed all supplemental testing and submitted …
Read More
About Monogram Orthopaedics, Inc. (MGRM)
- IPO Date 2023-05-18
- Website https://www.monogramorthopedics.com
- Industry Medical - Devices
- CEO Benjamin Sexson
- Employees 27